Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    Duloxetine, SSRIs Produce Similar Rates of Sexual Dysfunction in Patients With Depression: Presented at WCBP - (DGDispatch)
    TopAbstracts in Depression 07/01/2009 - (DGNews)
    Desvenlafaxine Reduces Anxiety Associated With Major Depressive Disorder: Presented at WCBP - (DGDispatch)
    Desvenlafaxine Is Effective for Major Depressive Disorder: Presented at WCBP - (DGDispatch)
    Armodafinil Improves Excessive Sleepiness Associated With Treated Obstructive Sleep Apnoea in Patients With Depression: Presented at ENS - (DGDispatch)

    News archive

     Recent webcasts/CME - Depression
      Treatment-Resistant Depression -- Part III: Switching Antidepressants vs. Conventional Augmentation Strategies
      On the Front Line of Major Depressive Disorder and Comorbidities: Managed Care and the Primary Care Physician
      Treatment-Resistant Depression -- Part II: Augmentation Strategies
      Treatment-Resistant Depression -- Part I: Introduction and Clinical Presentations
      Enhancing Treatment for Patients with Comorbid Depression, Diabetes and Heart Disease

      Webcasts/CME archive

       Recent cases - Depression
        Creutzfeldt-Jacob Disease Presenting as Severe Depression: A Case Report
        Sexual Dysfunction in a Young Mother
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
        Affective Psychosis, Hashimoto's Thyroiditis, and Brain Perfusion Abnormalities: Case Report

        Cases archive
          




        my personal edition > depression > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Sildenafil Improves Depression in Men With Erectile Dysfunction: Presented at CPA

        By Marvin Ross

        TORONTO, CANADA -- November 15, 2006 -- Men with erectile dysfunction (ED) and depression reported an improvement in both their depression and quality of life when successfully treated with sildenafil for their ED, according to research reported here in a poster presentation at the 56th Annual Meeting of the Canadian Psychiatric Association (CPA).

        Many men with erectile dysfunction also experience some symptoms of depression and decreased quality of life, said investigator Sidney H Kennedy, MD, professor of psychiatry and head, Mood and Anxiety Disorders Program, University of Toronto, Toronto, Ontario, Canada.

        Dr. Kennedy and colleagues therefore conducted a study to assess the effect of sildenafil on untreated depression in men with ED. Patients in the study met the Diagnostic and Statistical Manual - Revision IV criteria for dysthymia or depression, including minor depressive disorder but excluding any form of major depressive or psychotic disorder.

        The 6-week, double-blind, randomized, placebo-controlled study enrolled men with ED and a Beck Depression Inventory (BDI) II score of 14 to 28. The effect of treatment on the depressive symptoms was assessed with the BDI II and ED was measured with standard psychiatric questionnaires. Quality of life (QOL) was measured with the Patient Reported Erectile Function Assessment (PREFA).

        The study group consisted of 185 men with an average age of 51 years. Mean BDI II scores at baseline were 18.33 for placebo and 17.99 for the sildenafil group. The duration of depression was 3.32 years for the placebo group and 3.08 years for the sildenafil group. ED duration was 3.79 years and 4.06 years, respectively.

        After 6 weeks of treatment, the BDI II score for the placebo group was 13.58 and 9.52 for the treated group (P = .0001).

        Erections were achieved by 63% of the sildenafil group and 53% of the placebo group and the proportion of successful intercourse attempts was 77% for the sildenafil group and 40% for placebo (P < .0001).

        QOL as measured by the PREFA was also improved in men taking sildenafil compared with placebo (P < .0001).

        Adverse events were reported by 31% of the placebo group and 43% of the sildenafil group. Serious adverse events were seen in 2% for both groups.

        Dr. Kennedy concluded that sildenafil was well tolerated and that it helped to improve ED, depression and quality of life.


        [Presentation title: Sildenafil Improves Depressive Symptoms in Men With Erectile Dysfunction and Untreated Depression Not Otherwise Specified. Poster P 23]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send